BioSpace News Archive

Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced that the Board of Directors of the Company intends to initiate a process to evaluate the Company’s potential strategic alternatives to maximize value for stockholders.

Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 second quarter ended November 27, 2022.

Enzo Biochem, Inc. announced that it has entered into an agreement for Labcorp to acquire the assets of Enzo’s Clinical Laboratory division.

Jounce Therapeutics, Inc. (Nasdaq: JNCE) today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable responses based on a pre-planned informal data review.

YS Biopharma Co., Ltd. will become a publicly listed company trading on the Nasdaq Capital Market with its ordinary shares and warrants listed under the new ticker symbols “YS” and “YSBPW”, respectively.

Predictive Oncology Inc. today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on March 27, 2023.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highlighting clinical data from RUBY-1, a phase 1 healthy volunteer (HV) study of povetacicept, a dual B cell cytokine antagonist being developed for multiple B cell and/or autoantibody-related diseases.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 490,630 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it plans to implement a ratio change of the Company’s American Depositary Shares to its non-traded ordinary shares from the current ratio of one ADS representing ten ordinary shares to a new ratio of one ADS representing four hundred ordinary shares.